Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
2 studies found for:    rHIgM22
Show Display Options
Rank Status Study
1 Completed An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Drug: rHIgM22
2 Recruiting An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse
Condition: Multiple Sclerosis, Acute Relapsing
Interventions: Drug: rHIgM22;   Drug: Placebo

Study has passed its completion date and status has not been verified in more than two years.